Multi-omic phenotyping of inflammatory bowel disease (IBD)
Research type
Research Study
Full title
Multi-omic phenotyping of inflammatory bowel disease (IBD)
IRAS ID
243310
Contact name
Sharmili Balarajah
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
10 years, 0 months, 9 days
Research summary
The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC) are chronic diseases of the gastrointestinal tract, affecting 300-500 per 100,000 people in Europe; their incidence is rising. Despite significant advances in the fields of IBD genetics and immunology, the aetiopathogenesis of IBD is not fully understood. The aetiology is widely considered to involve an abnormal host immune response to a microbial stimulus in a genetically predisposed individual.
Current analyses of the gut microbiome have focused on describing the IBD colonic microbiome but have yet to describe the host-environment interactions that are of vital importance in host metabolism, and drug metabolism, in IBD.
Since 2005, our group has been using metabolic profiling technology to investigate the metabolic determinants of IBD and the role of the gut microbiome. This has resulted in 10 original research, high impact publications, as well as numerous published abstracts, reviews and editorials.
The current application is a continuation of previous studies, aiming specifically to investigate the metabolic and microbial influences of medications and surgery on IBD, as well as investigating different IBD phenotypes and related co-morbidities.
By exploring the impact of medical and surgical treatments, and correlating different IBD phenoytpes with their unique metabolic and microbial signatures, understanding at a molecular and genomic level will be enhanced.
Identification of specific metabolic and microbial determinants may allow enhanced patient stratification and more targeted therapies.
The study has been reviewed, and funding awarded, by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC).REC name
London - Stanmore Research Ethics Committee
REC reference
18/LO/1207
Date of REC Opinion
8 Aug 2018
REC opinion
Further Information Favourable Opinion